Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. Valued at $11.4 billion by market cap, the company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and TECH perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. TECH's commitment to innovation, strategic acquisitions, and global presence positions it for continued success. With a strong domestic foothold and international expansion opportunities, TECH is well-equipped to maintain its market share and drive growth.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Despite its notable strength, TECH slipped marginally from its 52-week high of $72.69, achieved on Sep. 22. Over the past three months, TECH stock gained 28.9%, outperforming the Nasdaq Composite’s ($NASX) 5.3% gains during the same time frame.
www.barchart.comIn the longer term, shares of TECH rose 23.3% on a YTD basis and climbed 37% over the past 52 weeks, outperforming NASX’s YTD gains of 15.9% and 19.3% returns over the last year.
To confirm the bullish trend, TECH has been trading above its 200-day moving average since late June. The stock has been trading above its 50-day moving average since early June, with minor fluctuations.
www.barchart.comTECH delivered mixed financial results, characterized by steady bottom-line net income growth alongside sluggish top-line revenue expansion. Sluggish biotech funding environment and uneven biopharma demand kept full-year sales mostly flat at $1.2 billion, while organic growth struggled to gain substantial traction across core instrument and diagnostic lines. However, disciplined cost controls, operational efficiencies, and targeted divestitures substantially improved GAAP operating margins and year over year net earnings. This operational resilience, coupled with an agreement to be acquired by Merck KGaA (MKGAF) helped support investor sentiment and spark a strong stock rally heading into late 2026 despite persistent top-line macro headwinds.
On Aug. 12, TECH shares closed up marginally after reporting its Q4 results. Its adjusted EPS of $0.52 met Wall Street expectations. The company’s revenue was $321.2 million, topping Wall Street forecasts of $317.2 million.
In the competitive arena of biotechnology, Adaptive Biotechnologies Corporation (ADPT) has massively taken the lead over TECH, showing resilience with 71.7% gains on a YTD basis and 100.2% returns over the past 52 weeks.
Wall Street analysts are cautious on TECH’s prospects. The stock has a consensus “Hold” rating from the 14 analysts covering it. While TECH currently trades above its mean price target of $71.08, the Street-high price target of $78 suggests a 7.6% upside potential.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
McDonald’s Increased Its Dividend by Nearly 4%. How to Play MCD Stock Here. Billionaire Mark Cuban Said He’d Trust a Seeing-Eye Dog Over a Self-Driving Car, ‘A Dog Will Recognize Adversarial Situations Better Than AI Can’ CoreWeave Priced an Upsized $3.7 Billion Convertible Note as Capex Spending Spikes. What That Means for CRWV Stock Fans. A $1 Billion Reason to Buy On Holdings Stock